clinical trial · NCT07642024
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
Sichuan Baili Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 90
Non-small Cell Lung CancerBL-B01D1OsimertinibCarboplatinPemetrexedCisplatin
brief summary
This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in resectable EGFR-mutant non-small cell lung cancer.
started
Jun 1, 2026
primary completion
Dec 1, 2032
completion
Dec 1, 2032
last updated
Jun 15, 2026
official title
A Phase II/III Randomized Controlled Clinical Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol